Marshall Wace North America’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Marshall Wace North America’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,369	Closed	-$526K	–	1868
2021 Q1	$526K	Sell	4,369 -82,159	-95%	-$9.31M	﹤0.01%	1188
2020 Q4	$8.79M	Hold	86,528	–	–	0.04%	412
2020 Q3	$6.69M	Sell	86,528 -23,852	-22%	-$2.03M	0.04%	344
2020 Q2	$12.3M	Hold	110,380	–	–	0.08%	245
2020 Q1	$7.95M	Buy	+110,380	New	+$9.44M	0.06%	248
2019 Q3	–	Sell	-50,325	Closed	-$1.01M	–	1602
2019 Q2	$1.01M	Buy	+50,325	New	+$1.01M	0.01%	749

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Marshall Wace North America's KRTX Position: Q2 2021 in Review

Marshall Wace North America sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2021, closing a stake of 4,369 shares — an estimated $526K sold.

Marshall Wace North America first reported a position in KRTX in Q2 2019 and held it in 6 quarters. The position peaked at $12.3M in Q2 2020. 159 funds tracked by Wall St. Rank hold KRTX as of Q2 2021.

Marshall Wace North America reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 4,369 Karuna Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $526K.
Marshall Wace North America first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Marshall Wace North America's Karuna Therapeutics, Inc. Common Stock position peaked at $12.3M in Q2 2020.
159 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.